Home›Research›Compare›CJC-1295 vs Sermorelin
Peptide ComparisonCJC-1295 vs Sermorelin
Both are GH / IGF Axis peptides.
CJC-1295
CJC-1295 DAC
Half-life: 6–8 days (DAC form)
445 providers listed
Sermorelin
GHRH 1-29
Half-life: 10–20 minutes
443 providers listed
CJC-1295 has a longer half-life than Sermorelin, so it generally needs less frequent dosing.
CJC-1295
Evidence
Half-life
6–8 days (DAC form)
Sermorelin
Evidence
Half-life
10–20 minutes
| Your goal | Better option |
|---|---|
| Extended half-life, fewer injections needed | CJC-1295 |
| More provider options (445 vs 443) | CJC-1295 |
| Longer clinical use record (FDA-approved history) | Sermorelin |
| Lower typical cost per treatment | Sermorelin |
| Natural GHRH analog (identical to endogenous fragment) | Sermorelin |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295
Sermorelin
CJC-1295
Sermorelin
About CJC-1295
CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.
About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
Sermorelin
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
CJC-1295
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
Sermorelin
Ipamorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
CJC-1295
Sermorelin
Where to source these peptides
CJC-1295
445 listed
Browse directory →
Providers offeringSermorelin
443 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 4, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 vs Sermorelin — Per-mg Price Comparison. Retrieved July 6, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/sermorelin